Iodine-131-meta-iodobenzylguanidine therapy for patients with newly diagnosed high-risk neuroblastoma.
CONCLUSIONS: We identified no RCTs or CCTs comparing the effectiveness of treatment including (131)I-MIBG therapy versus treatment not including (131)I-MIBG therapy in patients with newly diagnosed HR NBL. We found two small observational studies including chilren. They had high risk of bias, and not all relevant outcome results were available. Based on the currently available evidence, we cannot make recommendations for the use of (131)I-MIBG therapy in patients with newly diagnosed HR NBL in clinical practice. More high-quality research is needed.
PMID: 28429876 [PubMed - as supplied by publisher]
Source: Cochrane Database of Systematic Reviews - Category: Journals (General) Authors: Kraal KC, van Dalen EC, Tytgat GA, Van Eck-Smit BL Tags: Cochrane Database Syst Rev Source Type: research
More News: Cancer & Oncology | Cardiology | Cardiovascular | Cardiovascular & Thoracic Surgery | Children | Clinical Trials | Conferences | Databases & Libraries | General Medicine | Heart | History of Medicine | Hormones | Neuroblastoma | Neurology | Neurosurgery | Pediatrics | PET Scan | Stem Cell Therapy | Stem Cells | Study | Thyroid | Toxicology | Transplants